Celgene Announces Abraxane (Paclitaxel Injection) Plus Gemcitabine Prolongs Overall Survival in Metastatic Pancreatic Cancer

Share this content:
(ChemotherapyAdvisor) –  A newly-completed phase 3 clinical trial shows that Abraxane (paclitaxel injection) plus gemcitabine is associated with prolonged survival among patients with metastatic pancreatic cancer, according to an announcement by the Pancreatic Cancer Action Network and Celgene Corporation.

A multinational phase 3 study of 861 patients diagnosed with metastatic pancreatic cancer found “statistically significant improvement in overall survival” for patients receiving Abraxane injection plus gemcitabine, compared to patients receiving gemcitabine alone, according to the announcement.

“Historically, few effective treatment options for pancreatic cancer have existed,” said Julie Fleshman, president and CEO of the Pancreatic Cancer Action Network. “We are thrilled to have a new treatment option for patients with advanced pancreatic cancer.”

No statistical details have yet been released. Results from the study will be presented at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in January 2013, Celgene officials said.

“We look forward to learning more about the increase in survival when the full results from the study are released in January,” Fleshman stated, who added that clinical trials represent “the only way to make progress towards better treatments.”

Abraxane is paclitaxel modified by the addition of human albumin protein, according to the Celgene website. It was approved by the FDA in 2005 for breast cancer treatment. It was approved in October 2012 as a first-line treatment in combination with carboplatin for locally-advanced or metastatic non-small cell lung cancer (NSCLC) among patients who cannot undergo curative surgery or radiotherapy. Celgene also plans to seek FDA approval for Abraxane for the treatment of pancreatic cancer.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs